Serum VEGF Predicts Worse Clinical Outcome of Patients with Coronary Heart Disease After Percutaneous Coronary Intervention Therapy

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2015 Oct 27

PMID 26501555

Citations 8

Authors

Xia Han

Lili Liu

Jiamin Niu

Jun Yang

Zengtang Zhang

Zhiqiang Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Percutaneous coronary intervention (PCI) is an effective treatment for coronary heart disease (CHD) patients. However, patients after PCI treatment often have ischemic events that result in poor prognosis. Our study aimed to investigate the effects of vascular endothelial growth factor (VEGF) level on the prognosis of CHD patients.

Material And Methods: We enrolled 114 CHD patients in the study. Serum VEGF level was measured by enzyme-linked immunosorbent assay (ELISA). Total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and Hs-CRP were also tested in patients. The patients were divided into 2 groups according to the level of VEGF. Kaplan-Meier curve was used to observe the differences in survival situation of patients of the 2 groups. Cox regression analysis was conducted to judge whether VEGF was an independent biomarker for prognosis in CHD.

Results: We included 104 patients for survival analysis. VEGF level in CHD patients was significantly lower than that of healthy individuals (P<0.05). In the analysis of basic information, we found differences in sex distribution and hypertension between groups (P<0.05 for both). Kaplan-Meier curve indicated that patients with low expression of VEGF presented with poor prognosis. The mortality rate of the low-expression group was 37.71%, higher than that of the high-expression group (14.3%). Cox analysis suggested that VEGF could serve as a biomarker for prognosis in CHD (HR: 3.014, P: 0.019).

Conclusions: Low level of VEGF may predict poor clinical outcome of CHD patients after PCI treatment.

Citing Articles

Mechanisms of Myocardial Edema Development in CVD Pathophysiology.

Kiseleva D, Kirichenko T, Markina Y, Cherednichenko V, Gugueva E, Markin A Biomedicines. 2024; 12(2).

PMID: 38398066 PMC: 10887157. DOI: 10.3390/biomedicines12020465.

Heterogeneous nuclear ribonucleoprotein U-actin complex derived from extracellular vesicles facilitates proliferation and migration of human coronary artery endothelial cells by promoting RNA polymerase II transcription.

Wang H, Liu H, Zhao X, Chen X Bioengineered. 2022; 13(5):11469-11486.

PMID: 35535400 PMC: 9276035. DOI: 10.1080/21655979.2022.2066754.

Cholecalciferol supplementation lowers leptin and TMAO but increases NO and VEGF-A levels in obese vitamin D deficient patients: Is it one of the potential cardioprotective mechanisms of vitamin D?.

Ozorowski M, Wicinski M, Wrobel L, Fajkiel-Madajczyk A Nutr Metab (Lond). 2022; 19(1):31.

PMID: 35488267 PMC: 9052493. DOI: 10.1186/s12986-022-00666-4.

Serum VEGF: Diagnostic Value of Acute Coronary Syndrome from Stable Angina Pectoris and Prognostic Value of Coronary Artery Disease.

Huang A, Qi X, Cui Y, Wu Y, Zhou S, Zhang M Cardiol Res Pract. 2020; 2020:6786302.

PMID: 32411449 PMC: 7199618. DOI: 10.1155/2020/6786302.

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis.

Wicinski M, Gorski K, Wodkiewicz E, Walczak M, Nowaczewska M, Malinowski B Int J Mol Sci. 2020; 21(7).

PMID: 32218354 PMC: 7177465. DOI: 10.3390/ijms21072275.

References

Smit Y, Vlayen J, Koppenaal H, Eefting F, Kappetein A, Mariani M . Percutaneous coronary invervention versus coronary artery bypass grafting: a meta-analysis. J Thorac Cardiovasc Surg. 2014; 149(3):831-8.e1-13. DOI: 10.1016/j.jtcvs.2014.10.112. View

Ramos C, Napoleao P, Selas M, Freixo C, Viegas Crespo A, Mota Carmo M . Prognostic value of VEGF in patients submitted to percutaneous coronary intervention. Dis Markers. 2014; 2014:135357. PMC: 4109329. DOI: 10.1155/2014/135357. View

Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Savini C, Di Eusanio M . Risk of stroke with percutaneous coronary intervention compared with on-pump and off-pump coronary artery bypass graft surgery: Evidence from a comprehensive network meta-analysis. Am Heart J. 2013; 165(6):910-917.e14. DOI: 10.1016/j.ahj.2013.03.011. View

Kim S, Lee S, Park S, Kang S, Chung N, Shim W . Vascular endothelial growth factor, soluble fms-like tyrosine kinase 1, and the severity of coronary artery disease. Angiology. 2010; 62(2):176-83. DOI: 10.1177/0003319710370963. View

Javaid A, Steinberg D, Buch A, Corso P, Boyce S, Pinto Slottow T . Outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with drug-eluting stents for patients with multivessel coronary artery disease. Circulation. 2007; 116(11 Suppl):I200-6. DOI: 10.1161/CIRCULATIONAHA.106.681148. View

Liu H, Chen M, Yu J, Li W, Tao L, Li Y . Serum apelin level predicts the major adverse cardiac events in patients with ST elevation myocardial infarction receiving percutaneous coronary intervention. Medicine (Baltimore). 2015; 94(4):e449. PMC: 4602953. DOI: 10.1097/MD.0000000000000449. View

Bolognese L . Changing patterns of ST elevation myocardial infarction epidemiology. Am Heart J. 2010; 160(6 Suppl):S1-3. DOI: 10.1016/j.ahj.2010.10.008. View

Pollack Jr C, Hollander J, Chen A, Peterson E, Bangalore S, Peacock F . Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients.... Crit Pathw Cardiol. 2009; 8(1):29-33. DOI: 10.1097/HPC.0b013e3181980f9f. View

Kazmierczak E, Grajek S, Kowal J, Chmara E, Grygier M, Pyda M . Prognostic usefulness of IL-6 and VEGF for the occurrence of changes in coronary arteries of patients with stable angina and implanted stents. Eur Rev Med Pharmacol Sci. 2014; 18(15):2169-75. View

10.

Yang S, Piao J, Jin L, Zhou Y . Does pretreatment of bone marrow mesenchymal stem cells with 5-azacytidine or double intravenous infusion improve their therapeutic potential for dilated cardiomyopathy?. Med Sci Monit Basic Res. 2013; 19:20-31. PMC: 3638670. DOI: 10.12659/msmbr.883737. View

11.

De Sutter J, van de Veire N, Struyf S, Philippe J, De Buyzere M, Van Damme J . PF-4var/CXCL4L1 predicts outcome in stable coronary artery disease patients with preserved left ventricular function. PLoS One. 2012; 7(2):e31343. PMC: 3285621. DOI: 10.1371/journal.pone.0031343. View

12.

Konishi H, Miyauchi K, Kasai T, Tsuboi S, Ogita M, Naito R . Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention. Am J Cardiol. 2014; 115(2):157-60. DOI: 10.1016/j.amjcard.2014.10.015. View

13.

Shiomi H, Morimoto T, Furukawa Y, Nakagawa Y, Sakata R, Okabayashi H . Comparison of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Unprotected Left Main Coronary Artery Disease - 5-Year Outcome From CREDO-Kyoto PCI/CABG Registry Cohort-2 - . Circ J. 2015; 79(6):1282-9. DOI: 10.1253/circj.CJ-15-0034. View

14.

Zhang J, Wang J, Tang X, Yao Y, Zhang Y, Ma Y . Effect of platelet receptor gene polymorphisms on outcomes in ST-elevation myocardial infarction patients after percutaneous coronary intervention. Platelets. 2015; 27(1):75-9. DOI: 10.3109/09537104.2015.1034096. View

15.

Li Q, Chen L, Chen D, Wu X, Chen M . Influence of microRNA-related polymorphisms on clinical outcomes in coronary artery disease. Am J Transl Res. 2015; 7(2):393-400. PMC: 4399102. View

16.

Lopez A, Mathers C, Ezzati M, Jamison D, Murray C . Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006; 367(9524):1747-57. DOI: 10.1016/S0140-6736(06)68770-9. View

17.

Amoli M, Amiri P, Alborzi A, Larijani B, Saba S, Tavakkoly-Bazzaz J . VEGF gene mRNA expression in patients with coronary artery disease. Mol Biol Rep. 2012; 39(9):8595-9. DOI: 10.1007/s11033-012-1713-x. View

18.

Zhang Y, Iqbal J, van Klaveren D, Campos C, Holmes D, Kappetein A . Smoking is associated with adverse clinical outcomes in patients undergoing revascularization with PCI or CABG: the SYNTAX trial at 5-year follow-up. J Am Coll Cardiol. 2015; 65(11):1107-15. DOI: 10.1016/j.jacc.2015.01.014. View

19.

Konopka A, Janas J, Piotrowski W, Stepinska J . Concentration of vascular endothelial growth factor in patients with acute coronary syndrome. Cytokine. 2013; 61(2):664-9. DOI: 10.1016/j.cyto.2012.12.001. View

20.

Kwok C, Khan M, Rao S, Kinnaird T, Sperrin M, Buchan I . Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis. Circ Cardiovasc Interv. 2015; 8(4). DOI: 10.1161/CIRCINTERVENTIONS.114.001645. View